SCHEMBL1648202

SCHEMBL1648202

COC(=O)c1c(CS(=O)(=O)C2CC3CCC2CC3)ccc(Br)c1OC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
DRD2 P14416 2/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CYP2D6 P10635 1/20 0.34
ADRA2C P18825 1/20 0.34
DRD4 P21917 1/20 0.34
CYP2C19 P33261 1/20 0.34
ADRA1A P35348 1/20 0.34
DRD3 P35462 1/20 0.34
HTR2B P41595 1/20 0.34
KCNH2 Q12809 1/20 0.34
HIF1A Q16665 1/20 0.34
HSP90AA1 P07900 1/20 0.33
MEP1B Q16820 1/20 0.32
MAPT P10636 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1650155 0.85 MEN1 (0.36) SIGMAR1MEN1KMT2ADRD2HTR1A
SCHEMBL1648254 0.81 CNR2 (0.30)
SCHEMBL1648259 0.81 METAP2 (0.41)
SCHEMBL1648527 0.81 MEN1 (0.32) SIGMAR1MEN1KMT2ADRD2HTR1A
SCHEMBL1649232 0.80 SIGMAR1 (0.38) SIGMAR1MEN1KMT2ADRD2HTR1A
SCHEMBL18801138 0.80 HSP90AA1 (0.30) HSP90AA1
SCHEMBL16863821 0.79 MEN1 (0.33) SIGMAR1MEN1KMT2ADRD2HTR1A
SCHEMBL14725788 0.76 CA1 (0.38) SIGMAR1MEN1KMT2ADRD2HTR1A
SCHEMBL1648942 0.76 SIGMAR1 (0.38) SIGMAR1MEN1KMT2ADRD2HTR1A
SCHEMBL1648543 0.75 CA12 (0.37) SIGMAR1MEN1KMT2ADRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS SIGMAR1 2128/4885MEN1 1603/4885KMT2A 666/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS SIGMAR1 2128/4885MEN1 1603/4885KMT2A 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.